Get the app
US › Healthcare

NovaBridge Biosciences (NBP)

US · Healthcare · Biotechnology

$1.26-2.33%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Net profit
$-18.9M
EPS
$-0.07
EPS estimate
$-0.14

EPS came in at -0.07 against a street estimate of -0.14 — a beat of 50.0%.

Key statistics

Market cap
$161.8M
Forward P/E
2.7
P/B
0.88
Book value
$1.73
EPS (TTM)
$-0.69
52-week high
$6.79
52-week low
$1.31
50-day MA
$1.67
200-day MA
$2.39
Beta
1.60

Analyst view

Analysts rate NovaBridge Biosciences a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $9.00.

Shareholding

Insiders
14.28%
Institutions
34.23%

Largest institutional holders

FundStake
HHG PLC5.20%
Hillhouse Capital Advisors, Ltd.5.16%
Morgan Stanley - Brokerage Accounts3.15%
AIHC Capital Management Limited2.48%
Siren, L.L.C.1.73%
Marshall Wace Asset Management Ltd1.06%
Candriam Luxembourg S.C.A.0.98%
Adage Capital Partners Gp LLC0.86%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NovaBridge Biosciences — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.